TRAXV

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued NASDAQ

Healthcare ·Biotechnology ·US

$22.51

Mkt Cap $782.2M

52w Low $14.79 64.3% of range 52w High $26.80

50d MA $21.41 200d MA $21.41

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity —

ROE —

P/FCF —

RSI (14) —

ATR (14) —

Beta 0.00

50d MA $21.41

200d MA $21.41

Avg Volume 265.5K

About

First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.

Recent Filings

8-K

First Tracks Biotherapeutics, Inc. -- 8-K Filing

First Tracks Biotherapeutics has separated from AnaptysBio through a spin-off transaction, creating an independent public company with its own governance and operational structure going forward.

Apr 20

8-K

AnaptysBio, Inc. -- 8-K Filing

AnaptysBio completed a spin-off creating First Tracks Biotherapeutics, with detailed agreements governing asset transfers, liability assumptions, and ongoing relationships between the two independent entities.

Apr 20

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

This Regulation FD disclosure likely contains forward-looking statements about company plans or expectations, signaling management's optimistic outlook but with limited legal liability if projections fail to materialize.

Apr 3

Data updated apr 30, 2026 5:05pm · Source: massive.com